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Glutathione S-transferase activity during pregnancy in the mouse: effects of trans- 
stilbene oxide pretreatment 
(Received 2 June 1983; accepted 23 April 1984) 
Thioether formation catalyzed by glutathione S-trans- 
ferases (GSHTr, EC 2.5.1.18) represents one of the major 
mechanisms of in uiuo detoxication of xenobiotics (l-31. 
Recent studies have shown that metabolism of vicinal dihal- 
ogens by GSHTr may lead to formation of potent mutagens 
[4-61. In mammals, essentially all organs are known to 
possess this enzyme system [l, 71. In contrast to the liver, 
which contains several forms of GSHTr [l], human placenta 
is reported to possess a single form of this enzyme [8,9], 
and its activity is not altered following exposure of pregnant 
women to tie constituents of cig&ettk smoke’[lO: 111. 
GSHTr activity has also been detected in the placentas of 
rabbits, guinea pigs [12, 131, rats [14], and monkeys [15]. 
Data are also available on the changes in the titers of 
placental GSHTr with gestational age in rabbits and guinea 
pigs [12, 131. However;similar infoymation is not available 
at present for the mouse placental enzyme. 
Because of obvious pharmaco-toxicological implications, 
alterations in the drug-metabolizing enzymes following 
exposure of pregnant animals to different chemicals have 
received considerable attention [l&23]. Most of these 
investigations deal with cytochrome P-450-dependent 
monooxygenase activity, and little is known about the 
effects these chemicals have on GSHTr. Earlier, Bell et 
al. [22] reported noninducibility of hepatic GSHTr after 
treatment of pregnant rats with the classical inducer oheno- 
barbital. However, in subsequent studies by Rouei et al. 
1231, induction of liver GSHTr was observed in ureenant . . I a 
rats and mice exposed to 5,6_benzoflavone. In these 
reports, possible alteration in the placental GSHTr was not 
considered. Thus, the question of inducibility of GSHTr 
during pregnancy warrants further examination. Although 
in males of both mice and rats the liver GSHTr are inducible 
enzymes and a number of chemicals including pesticides 
and carcinogens have been shown to be inducers, the mouse 
liver enzymes seem to be more responsive [l, 24,251. 
Therefore, the objectives of the present study were to 
examine (i) the quantitative changes in the mouse hepatic 
and placental GSHTr activity due to pregnancy, and (ii) 
the effects of exposure to a potent inducer of this enzyme 
system, namely trans-stilbene oxide (TSO) [26-281. 
Materials and methods 
Young virgin mice of the CD1 strain were purchased 
from the Charles River Breeding Laboratories and housed 
for at least 1 week prior to use. Purina 5001 mouse chow 
and water were given ad lib. Animal rooms were on a 12- 
hr light/dark schedule. The date on which a mating plug 
was observed was designated as day zero of pregnancy. 
TSO (Aldrich Chemical Co.) in corn oil was administered 
intraperitoneally once daily for 3 days on either days 9, 10, 
and 11 or on days 15, 16 and 17 of gestation at doses of 0 
(control), 100,300, or 500 mg/kg. Animals were killed 24 hr 
after the last dose (on day 12 or 18 of gestation) by cervical 
dislocation. Placentas and livers were examined in situ for 
signs of toxicity, removed quickly, weighed, and placed in 
cold 50 mM Tris buffer, pH 7.4, containing 0.25 M sucrose 
and 1.0 mM EDTA. Placentas were pooled by litter while 
maternal livers were processed individually to isolate cyto- 
sol by differential centrifugation [25]. 
Cytosolic GSHTr activity was assayed spectrophoto- 
metrically at 37” using 105,OOOg supernatant fluid as the 
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enzyme source and 1 mM l-chloro-2.4-dinitrobenzene 
(CDNB) and 1 mM reduced glutathione (GSH) as co- 
substrates, according to Habig et al. 1291. 
Results and discusszon 
The effects of pregnancy on maternal liver GSHTr 
activity are shown in Fig. 1. Although the values observed 
in pregnant animals were slightly lower as compared to 
non-pregnant controls, there was no statistically significant 
change in GSHTr titers in relation to gestational stage. 
Polidoro et al. [14] also reported similar observations for 
liver GSHTr activity towards CDNB and 1,2-dichloro-4- 
nitrobenzene (DCNB) at mid-pregnancy compared to non- 
pregnant rats. However, liver cytosols from i9- to 20-day 
pregnant rats exhibited a significant increase in CDNB and 
a decrease in DCNB conjugation activity. Their data also 
indicated that GSHTr activity againstp-nitrobenzyl~hloride 
did not change while that towards 1,2-epoxy-3-(p-nitro- 
phenoxy) propane increased due to pregnancy. Earlier, 
Combes and Stakelum [30] observed depression in sul- 
fobromophthalein conjugation with GSH in the livers of 
pregnant rats. James el al. [13] reported that hepatic GSHTr 
activity toward styrene oxide measured in pooled samples 
of pregnant guinea pigs tended to be slightly lower than 
in comparable samples from adult males. These reports 
suggest that the changes in liver GSHTr during pregnancy 
are unpredictable and vary with each substrate in different 
animal species. 
The pretreatment of pregnant mice with TSO resulted in 
a significant induction of GSHTr in the maternal liver 
except for the samples examined from Q-day and 18- 
day pregnant mice receiving 100 mg TSO/kg (Fig. 1). The 
magnitude of induction was found to be dose dependent 
and a maximum of about 3.4-fold increase in activity was 
observed in l&day pregnant mice receiving 500 mg TSO/ 
kg. Earlier reports [26-281 have shown a 2- to 4-fold induc- 
tion of liver GSHTr in male rats pretreated with TSO and 
the induction was believed to be due to TSO itself and not 
due to its metabolites [27]. Since isozymes of GSHTr from 
different sources exhibit overlapping substrate specificity 
and CDNB serves as a substrate for all the forms [l], it 
remains unknown whether certain or all of the isozymes of 
pregnant mouse liver GSHTr are induced by TSO 
pretreatment. 
The pregnant mice treated with TSO appeared healthy 
and active and continued to gain weight. The great majority 
of fetuses appeared normal when inspected at sacrifice. 
Occasionally mice receiving 500 mg TSO/kg exhibited some 
signs of toxicity as evidenced by pale fetuses and discolored 
placentas. These placentas were not included in enzyme 
preparations. 
Figure 2 shows the changes in the mouse placental 
GSHTr activity during pregnancy and the effects of TSO 
pretreatments. At present it is unknown whether the mouse 
placenta, similar to the human placenta [8,9], possesses 
onlv one form of GSHTr. The data indicate that in un- 
treated mice the GSHTr titers were essentially the same at 
day 12 and day 18 of gestation. However, using CDNB as 
a co-substrate, Polidoro ef al. [4] reported about a 50% 
decrease in rat placental GSHTr activity near term relative 
to mid-pregnancy. It should be noted, however, that only 
one sample was examined. On the other hand, no such 
dramatic changes but a relatively small gradual decline has 
been observed during pregnancy in rabbit and guinea pig 
placental GSHTr activity toward CDNB [12, 131. In 
humans, placental GSHTr activity utilizing styrene oxide 
as a substrate apparently remains nearlv constant between 
8 and 25 weeks- of gestation followed by about a 50% 
decline at full term 1101. A similar dramatic droo in GSHTr 
& , 
activity towards styrene oxide was observed in guinea pig 
but not in rabbit placentas [12, 131 towards the end of 
gestation. Taken together, these reports tend to suggest 
that. during pregnancy, substrate as well as species-specific 
ray 12 m&Y $8 Day 12 Day ,a 
Fig. 1. Maternal liver glutathione S-transferase activity 
during pregnancy and the effects of irnrzs-stilbene oxide 
pretreatment. The pretreatment of pregnant mice and the 
measurement of liver cytosolic enzyme activity were per- 
formed as described in Materials and Methods. Each bar 
representsmeanspecificactivity ? S.E.M. (N = 5-12). The 
specific activity is expressed as nmoles of CDNB 
conjugated/mm/per g liver (A) or per mg cytosolic protein 
(B). The specific activity in non-pregnant mice was 
1.64 + 0.16 ~moles/min/mg protein or 216 rt 27 pmoles/ 
min/g liver (N = 5). Key: (*) Significantly different from 
control (P < 0.001). 
differences exist in the titers of placental GSHTr. activity. 
The data given in Fig. 2 also indicate that none of the TSO 
treatments produced changes in placental GSHTr activities 
that were significantly different from controls. Comparative 
data on the TSO-caused alterations in placental GSHTr are 
not currently available for other animal species. In view of 
the reported ability of TSO to cause induction of GSHTr 
in the extrahepatic tissues [28], the observed lack of induc- 
tion of the mouse placental enzyme was rather unexpected. 
Although these observations suggest that placental GSHTr. 
in general, may be refractory to the inductive effects of 
environmental chemicals, additional data are needed. 
In conclusion, the data obtained under the experimental 
conditions employed indicate the inducibility of liver but 
not of placental GSHTr in the mouse during pregnancy. 
Utilizing TSO, the magnitude of induction was dose depen- 
dent and is quite comparable to that reported for the male 
rat. 
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Fig. 2. Placental glutathione S-transferase activity during 
pregnancy and the effects of frans-stilbene oxide pre- 
treatment. The experimental details are the same as given 
in the legend for Fig. 1. The specific activity is expressed 
as nmoles of CDNB conju ated/min per g tissue (A) or 
nmoles CDNB conjugate dp. mm per mg cytosolic protein 
tB). 
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Evidence for generation of leukotriene B4 in human polymorphonuclear leukocytes 
treated with linoleylanilide 
(Received 2 April 1984; accepted 28 May 1984) 
In resting human polymorphonuclear leukocytes (PMNs) 
the free levels of arachidonic acid are low. However, upon 
stimulation, the levels of arachidonic acid rapidly increase 
[l-3]. The interest in the study of the mechanisms by which 
the intracellular levels of arachidonic acid are controlled 
has grown during the last years (reviewed in [4]). This is 
due to the finding that arachidonic acid is precursor of the 
leukotrienes, which are potent mediators of the inflam- 
matory response (reviewed in [5]). We have previously 
shown that linoleylanilide, a fatty acid anilide supposely 
involved in the toxic syndrome in Spain [6,7], induces the 
generation of arachidonic acid from human PMNs [3]. 
Different to other signals, like phagocitic particles or the 
ionophore A23187 [l, 21, linoleylanilide induces the gen- 
eration of arachidonic acid without affecting the synthesis 
of PAF-acether, lysosomal enzymes or O:- [3]. This permits 
us to explore the mechanisms that control arachidonic acid 
metabolism in human polymorphonuclear leukocytes with 
relative independence of other processes. In this study we 
have investigated the following questions: (1) From which 
phospholipids is arachidonic acid generated in response to 
linoleylanilide? (2) By which mechanisms is arachidonic 
acid generated in response to linoleylanilide? (3) Is the 
arachidonic acid generated in response to linoleylanilide 
retained intracellularly or is it released to the extracellular 
medium? and (4) is the arachidonic acid generated in 
response to linoleylanilide metabolized by the lipoxygenase 
pathway? 
Materials and methods 
Cells. Human PMNs were obtained from venous blood 
of normal volunteers as in [8]. 
Effect of linoleylanilide on the content in arachidonic acid 
of phosphatidylcholine and phosphatidylinositol. Human 
PMNs were labelled with (5,6,8,9,11,12,14,15-[3H])- 
arachidonic acid (Amersham, 125 Ci/mmole) as previously 
described [2, 31. After washing, PMNs (0.6 ml, 1 x 10’cells 
per ml) were incubated with linoleylanilide (1 mg/ml) for 
2 hr at 37”. After extraction, lipids were subjected to TLC 
in chloroform/methanol/acetic acid/sodium borate 0.1 M 
